Cotización AN2 Therapeutics - ANTX

Herramientas de nivel profesional para inversores individuales.

Premium

Último Precio

1.065

Postura de Compra

1.06

Postura de Venta

1.07

Volume Operado de la Acción

182,471

1.05 Rango del Día 1.08

0.87 Rango de 52 semanas 22.22

Capitalización de Mercado [m]

31.782M

Precio Anterior

1.06

Precio de Apertura

1.06

Hora

1.06

Última hora de negociación

12:28:40

Volumen financiero

US$ 194,622

Precio Promedio Ponderado

1.0666

Volumen promedio (3 m)

635,224

Acciones en circulación

29,842,431

Rendimiento del Dividendo

Ratio Precio/Utilidad

-0.49

Beneficio por acción (BPA)

-2.17

turnover

Beneficio neto

-64.73M

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.an2therapeutics.com

Sede

Dover, Delaware, USA

Fundado

AN2 Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANTX. The last closing price for AN2 Therapeutics was US$1.06. Over the last year, AN2 Therapeutics shares have traded in a share price range of US$ 0.87 to US$ 22.22.

AN2 Therapeutics currently has 29,842,431 shares in issue. The market capitalisation of AN2 Therapeutics is US$31.63 million. AN2 Therapeutics has a price to earnings ratio (PE ratio) of -0.49.

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

EBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with MAC lung disease AN2 plans to shift focus to internal boron...

Form 4 - Statement of changes in beneficial ownership of securities

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0.02	1.91387559809	1.045	1.09	1.01	188741	1.05050091	CS
4	-0.035	-3.18181818182	1.1	1.19	1.01	387305	1.09347807	CS
12	-1.025	-49.043062201	2.09	3.07	0.87	635224	1.24645276	CS
26	-1.885	-63.8983050847	2.95	3.88	0.87	416046	1.70555307	CS
52	-13.215	-92.5420168067	14.28	22.22	0.87	320344	3.92304587	CS
156	-15.785	-93.6795252226	16.85	23.58	0.87	165702	5.54376413	CS
260	-15.785	-93.6795252226	16.85	23.58	0.87	165702	5.54376413	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
ZEOZeo Energy Corporation	US$ 2.4215 (112.41%)	56.35M
GSIWGarden Stage Ltd	US$ 4.72 (107.93%)	44.91M
TBIOTelesis Bio Inc	US$ 2.75 (102.21%)	49.7M
XCURExicure Inc	US$ 3.78 (65.07%)	15.96M
GLMDGalmed Pharmaceuticals Ltd	US$ 11.0147 (59.63%)	32.97M
HAOHaoxi Health Technology Ltd	US$ 0.7699 (-74.34%)	6.78M
HOVRNew Horizon Aircraft Ltd	US$ 0.4653 (-37.21%)	2.45M
GDHGGolden Heaven Group Holdings Ltd	US$ 2.72 (-34.77%)	441.24k
PGNYProgyny Inc	US$ 16.70 (-31.67%)	12.68M
XCHXCHG Ltd	US$ 12.65 (-31.14%)	1.18M
NVDANVIDIA Corporation	US$ 119.465 (5.38%)	180.57M
SQQQProShares UltraPro Short QQQ	US$ 7.665 (-8.75%)	152.55M
MAXNMaxeon Solar Technologies Ltd	US$ 0.1011 (11.22%)	85.84M
FRGTFreight Technologies Inc	US$ 0.1267 (2.26%)	76.06M
HOLOMicroCloud Hologram Inc	US$ 0.2609 (28.97%)	71.04M